CoChat

Inhibitors of Advanced Glycation End Product Formation and Neurovascular Dysfunction in Experimental Diabetes

CAMERON, NORMAN E., GIBSON, T MICHAEL, NANGLE, MATTHEW R., COTTER, MARY A. · 2005 · Annals of the New York Academy of Sciences
Cited by 112

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

A bstract: Advanced glycation and lipoxidation end products (AGEs/ALEs) have been implicated in the pathogenesis of the major microvascular complications of diabetes mellitus: nephropathy, neuropathy, and retinopathy. This article reviews the evidence regarding the peripheral nerve and its vascular supply. Most investigations done to assess the role of AGEs/ALEs in animal models of diabetic neuropathy have used aminoguanidine as a prototypic inhibitor. Preventive or intervention experiments have shown treatment benefits for motor and sensory nerve conduction velocity, autonomic nitrergic neurotransmission, nerve morphometry, and nerve blood flow. The latter depends on improvements in nitric oxide‐mediated endothelium‐dependent vasodilation and is responsible for conduction velocity improvements. A mechanistic interpretation of aminoguanidine's action in terms of AGE/ALE inhibition is made problematic by the relative lack of specificity. However, other unrelated compounds, such as pyridoxamine and pyridoxamine analogues, have recently been shown to have beneficial effects similar to aminoguanidine, as well as to improve pain‐related measures of thermal hyperalgesia and tactile allodynia. These data also stress the importance of redox metal ion‐catalyzed AGE/ALE formation. A further approach is to decrease substrate availability by reducing the elevated levels of hexose and triose phosphates found in diabetes. Benfotiamine is a transketolase activator that directs these substrates to the pentose phosphate pathway, thus reducing tissue AGEs. A similar spectrum of improvements in nerve and vascular function were noted when using benfotiamine in diabetic rats. Taken together, the data provide strong support for an important role for AGEs/ALEs in the etiology of diabetic neuropathy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1196/annals.1333.091

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 112

Metadata

Authors
CAMERON, N. E., GIBSON, T. M., NANGLE, M. R., & COTTER, M. A.
Venue
Annals of the New York Academy of Sciences
Publisher
Wiley
Published
2005-06
Volume
1043
Issue
1
Pages
784-792
ISSN
  • 0077-8923 (ISSN-L)
  • 1749-6632
OpenAlex
W2073715063
Cited by
112
References
2
FWCI
3.25
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibitors of Advanced Glycation End Product Formation and Neurovascular Dysfunction in Experimental Diabetes. https://app.cochat.ai/papers/10.1196/annals.1333.091
The paper
CAMERON, N. E., GIBSON, T. M., NANGLE, M. R., & COTTER, M. A. (2005). Inhibitors of Advanced Glycation End Product Formation and Neurovascular Dysfunction in Experimental Diabetes. Annals of the New York Academy of Sciences. https://doi.org/10.1196/annals.1333.091

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.